The evolution of combined oral contraception: Improving the risk-to-benefit ratio

Contraception

Volumn 84, Issue 1, 2011, Pages 19-34

  Burkman, Ronald ^a   Bell, Carrie ^a   Serfaty, David ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Francophone Society of Contraception   (France)

Author keywords

Combined oral contraceptives; Efficacy; Estrogen; Progestin; Safety

Indexed keywords

CHLORMADINONE ACETATE; COPPER INTRAUTERINE DEVICE; CYPROTERONE ACETATE; DEMEGESTONE; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; ETONOGESTREL; ETYNODIOL DIACETATE; GESTAGEN; LOW DOSE ORAL CONTRACEPTIVE; LYNESTRENOL; MEDROGESTONE; MEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETYNODREL; ORAL CONTRACEPTIVE AGENT; PROMEGESTONE;

BINDING AFFINITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONDOM; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE STERILIZATION; HORMONAL CONTRACEPTION; HUMAN; LUNG EMBOLISM; MALE STERILIZATION; MENSTRUAL CYCLE; ORAL CONTRACEPTION; REVIEW; RISK BENEFIT ANALYSIS; TRANSDERMAL PATCH; VAGINA RING;

BIOMEDICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 79958767118     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.11.004     Document Type: Review

References (168)

1. United Nations Department of Economic and Social Affairs. World contraceptive use 2007. 2007.
2. Blackburn RD, Cunkelman JA, Zlidar VM. Oral contraceptives - an update. Population reports, Series A, No. 9. Baltimore (MD): Johns Hopkins University School of Public Health, Population Information Program; 2000.
3. Save the children. State of the world's mothers 2007: saving the lives of children under 5. Westport (CT): Save the Children; 2007.
4. Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970;2:203-9.
5. Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception 2008;78:4-9.
6. Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008;34:237-46.
7. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 microg versus >20 microg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2008:CD003989.
8. Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008;77:1-5.
9. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999;60:321-9. (Pubitemid 30133220)
10. Jordan WM. Pulmonary embolism. Lancet 1961:1146-7.
11. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP, Enhancement by factor V. Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
12. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed) 1986;292:526. (Pubitemid 16126103)
13. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.
14. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187-96. (Pubitemid 34258539)
15. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.
16. Sidney S, Petitti DB, Quesenberry Jr CP, Klatsky AL, Ziel HK, Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol 1996;88:939-44. (Pubitemid 26394306)
17. Rosenberg L, Palmer JR, Lesko SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 1990;131:1009-16. (Pubitemid 20178622)
18. Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol 1991;98:1245-53.
19. Margolis KL, Adami HO, Luo J, Ye W, Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007;88:310-6. (Pubitemid 47212162)
20. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005;90:3863-70. (Pubitemid 41058144)
21. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3-63. (Pubitemid 41232429)
22. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas 2008;61:171-80.
23. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas 2003;46(Suppl 1):S7-S16. (Pubitemid 37506058)
24. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78. (Pubitemid 43231449)
25. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582-8.
26. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93. (Pubitemid 26001840)
27. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83-8.
28. Armstrong JL, Reid M, Bigrigg A. Scare over oral contraceptives. Effect on behaviour of women attending a family planning clinic. BMJ 1995;311:1637.
29. Child TJ, MacKenzie IZ, Rees M. Terminations of pregnancy, not unplanned deliveries, increased as result of pill scare. BMJ 1996;313:1005. (Pubitemid 26385534)
30. Dillner L. Pill scare linked to rise in abortions. BMJ 1996;312:996.
31. Iversen OE, Nilsen ST. The recent pill scare and number of legal abortions in Norway. Acta Obstet Gynecol Scand 1996;75:690-1. (Pubitemid 26302274)
32. Heinemann LA. The changing scene - an unnecessary pill crisis. Hum Reprod Update 1999;5:746-55.
33. Heinemann LA, Garbe E, Farmer R, Lewis MA. Venous thromboembolism and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur J Contracept Reprod Health Care 2000;5:183-91.
34. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-6.
35. Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae KD, Tyrer F, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000;49:580-90. (Pubitemid 30326558)
36. Heinemann LA, Lewis MA, Assmann A, Thiel C. Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception 2002;65:207-14.
37. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:131-4. (Pubitemid 32678382)
38. Lewis MA. The Transnational Study on Oral Contraceptives and the Health of Young Women. Methods, results, new analyses and the healthy user effect. Hum Reprod Update 1999;5:707-20.
39. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999;14:1493-9. (Pubitemid 29265441)
40. Corson SL. Increased risk from third-generation progestogens: fuzzy logic or fuzzy science? J Reprod Med 1996;41:711-2.
41. Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998;57:211-30.
42. Jick H, Jick SS, Myers MW, Vasilakis C. Third-generation oral contraceptives and venous thrombosis. Lancet 1997;349:731-2 author reply 732-3.
43. Lidegaard O, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996;53:135-9. (Pubitemid 126351296)
44. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997;177:887-91. (Pubitemid 27516062)
45. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000;15:817-21.
46. Todd J, Lawrenson R, Farmer RD, Williams TJ, Leydon GM. Venous thromboembolic disease and combined oral contraceptives: a reanalysis of the MediPlus database. Hum Reprod 1999;14:1500-5. (Pubitemid 29265442)
47. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8. (Pubitemid 27023424)
48. Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998;57:67-70. (Pubitemid 28208475)
49. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006;73:566-70.
50. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54.
51. Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981;305:420-4. (Pubitemid 11047042)
52. Mann JI, Inman WH. Oral contraceptives and death from myocardial infarction. Br Med J 1975;2:245-8.
53. Mann JI, Thorogood M, Waters WE, Powell C. Oral contraceptives and myocardial infarction in young women: a further report. Br Med J 1975;3:631-2.
54. Mann JI, Doll R, Thorogood M, Vessey MP, Waters WE. Risk factors for myocardial infarction in young women. Br J Prev Soc Med 1976;30:94-100.
55. Mann JI, Inman WH, Thorogood M. Oral contraceptive use in older women and fatal myocardial infarction. Br Med J 1976;2:445-7.
56. Mann JI, Vessey MP, Thorogood M, Doll SR. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J 1975;2:241-5.
57. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988;319:267-73.
58. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989;298:165-8. (Pubitemid 19039682)
59. Goldbaum GM, Kendrick JS, Hogelin GC, Gentry EM. The relative impact of smoking and oral contraceptive use on women in the United States. JAMA 1987;258:1339-42. (Pubitemid 17132839)
60. Petitti DB, Sidney S, Quesenberry CP. Oral contraceptive use and myocardial infarction. Contraception 1998;57:143-55. (Pubitemid 29281901)
61. Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Stolley PD, Shapiro S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 1985;253:2965-9. (Pubitemid 15032444)
62. Shapiro S, Slone D, Rosenberg L, Kaufman DW, Stolley PD, Miettinen OS. Oral-contraceptive use in relation to myocardial infarction. Lancet 1979;1:743-7.
63. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997;349:1202-9.
64. Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999;318:1579-83.
65. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787-93.
66. Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 2002;17:2307-14. (Pubitemid 35021451)
67. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009;53:221-31.
68. Cohen J. Clinical use of biphasic and triphasic pills. IPPF Med Bull 1985;19:1-2.
69. Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006;3:CD003283.
70. Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006;3:CD002032.
71. Kaunitz AM, Burkman RT, Fisher AC, Laguardia KD. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol 2009;114:1205-12.
72. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005;71:409-16. (Pubitemid 40725775)
73. Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception 2009;80:445-51.
74. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007;75:16-22. (Pubitemid 44854856)
75. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89-96. (Pubitemid 37101032)
76. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73:229-34. (Pubitemid 43202171)
77. YAZ [package insert]. Wayne (NJ): Bayer HealthCare Pharmaceuticals; 2007.
78. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005: CD004695.
79. Legro RS, Pauli JG, Kunselman AR, Meadows JW, Kesner JS, Zaino RJ, et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008;93:420-9. (Pubitemid 351240811)
80. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75:444-9. (Pubitemid 46764300)
81. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003;101:653-61. (Pubitemid 36390051)
82. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006;74:439-45. (Pubitemid 46037535)
83. Hirvonen E, Allonen H, Anttila M, Kulmala Y, Ranta T, Rautiainen H, et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas 1995;21:27-32.
84. Hoffmann H, Moore C, Zimmermann H, Elger W, Schwarz S, Graser T, et al. Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol 1998;50:458-64.
85. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril 1993;60:616-9. (Pubitemid 23298503)
86. Koetsawang S, Mandlekar AV, Krishna UR, Uurandare VN, Deshpande CK, Chew SC, et al. Task Force on Oral Contraceptives. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception. Contraception 1980;21:445-59.
87. Hoy SM, Scott LJ. Estradiol valerate/dienogest: in oral contraception. Drugs 2009;69:1635-46.
88. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 2008;78:218-25.
89. Duc I, Botella J, Bonnet P, Fraboul F, Delansorne R, Paris J. Antiandrogenic properties of nomegestrol acetate. Arzneimittelforschung 1995;45:70-4.
90. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151-7.
91. Couzinet B, Young J, Kujas M, Meduri G, Brailly S, Thomas JL, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab 1999;84:4191-6. (Pubitemid 30644216)
92. Botella J, Porthe-Nibelle J, Paris J, Lahlou B. Interaction of new 19 nor progesterone derivatives with progestagen, mineralocorticoid and glucocorticoid cytosolic receptors. J Pharmacol 1986;17:699-706. (Pubitemid 17036239)
93. Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995;55:239-46.
94. Ezan E, Benech H, Bucourt R, Ardouin T, Tchernatinsky C, Thomas JL, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993;46:507-14. (Pubitemid 23312322)
95. Bazin B, Thevenot R, Bursaux C, Paris J. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol 1987;94:1199-204. (Pubitemid 18058561)
96. Jamin C, Batallan A, Madelenat P. Antigonadotropic effects of a 19- nor-progesterone derivative: the example of nomegestrol acetate. Gynecol Obstet Fertil 2003;31:70-81. (Pubitemid 36427068)
97. Basdevant A, Pelissier C, Conard J, Degrelle H, Guyene TT, Thomas JL. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991;44:599-605.
98. Dorangeon P, Thomas JL, Choisy H, Lumbroso M, Hazard MC. Effects of nomegestrol acetate on carbohydrate metabolism. Diabetes Metab 1993;19:441-5. (Pubitemid 24039446)
99. Chabbert-Buffet N. Synergistic effect of 17 β-estradiol and nomegestrol acetate used in a new monophasic oral contraceptive. Presented at the 8th Congress of the European Society of Gynecology, September; 2009. Rome (Italy).
100. Serfaty D, Christin Maitre S, Ochsenbein E, Thomas J-L. Comparison of two regimens of new monophasic oral contraceptive combining 17 beta-estradiol and nomegestrol acetate. Presented at XIX FIGO World Congress of Gynecology and Obstetrics October 4-9; 2009. Cape Town (South Africa).
101. World Health Organization GI. Facts on induced abortion worldwide. World Health Organization, Guttmacher Institute; 2007.
102. Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. National Center for Health Statistics. Vital Health Stat 2005:23.
103. Frost JJ, Singh S, Finer LB. U.S. women's one-year contraceptive use patterns, 2004. Perspect Sex Reprod Health 2007;39:48-55.
104. Bongaarts J, Bruce J. The causes of unmet need for contraception and the social content of services. Stud Fam Plann 1995;26:57-75. (Pubitemid 26429723)
105. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-5.
106. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749-56. (Pubitemid 13053503)
107. Hulka BS, Chambless LE, Kaufman DG, Fowler Jr WC, Greenberg BG. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 1982;247:475-7. (Pubitemid 12203031)
108. Kaufman DW, Shapiro S, Slone D, Rosenberg L, Miettinen OS, Stolley PD, et al. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med 1980;303:1045-7. (Pubitemid 10025217)
109. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 1980;302:551-4. (Pubitemid 10184280)
110. Ramcharan S, Pellegrin FA, Ray R, Hsu JP. The Walnut Creek Contraceptive Drug Study: a prospective study of the side effects of oral contraceptives. Vol. 3. An interim report - a comparison of disease occurrence leading hospitalization or death in users and nonusers of oral contraceptives. Bethesda (MD): US: Department of Health and Human Services, National Institute of Child Health and Human Behavior; 1985, p. 349.
111. Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Mostow ED, Schwartz PE, et al. A case-control study of cancer of the endometrium. Am J Epidemiol 1982;116:333-42. (Pubitemid 12048413)
112. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999;318:96-100. (Pubitemid 29188927)
113. Fernandez E, La Vecchia C, Franceschi S, Braga C, Talamini R, Negri E, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998;9:295-300. (Pubitemid 28194239)
114. Furner SE, Davis FG, Nelson RL, Haenszel W. A case-control study of large bowel cancer and hormone exposure in women. Cancer Res 1989;49:4936-40. (Pubitemid 19213651)
115. Martinez ME, Grodstein F, Giovannucci E, Colditz GA, Speizer FE, Hennekens C, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1997;6:1-5. (Pubitemid 27030419)
116. Potter JD, McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst 1983;71:703-9. (Pubitemid 14232383)
117. Kune GA, Kune S, Watson LF. Oral contraceptive use does not protect against large bowel cancer. Contraception 1990;41:19-25. (Pubitemid 20018635)
118. Troisi R, Schairer C, Chow WH, Schatzkin A, Brinton LA, Fraumeni Jr JF. Reproductive factors, oral contraceptive use, and risk of colorectal cancer. Epidemiology 1997;8:75-9. (Pubitemid 27014225)
119. Weiss NS, Daling JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst 1981;67:57-60. (Pubitemid 11087551)
120. 9th Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
121. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385-9.
122. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007;335:651.
123. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-32. (Pubitemid 34680593)
124. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006;81:1290-302. (Pubitemid 44484967)
125. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L. Hormonal contraception and risk of cancer. Hum Reprod Update.
126. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1-K16.
127. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-92. (Pubitemid 34270731)
128. Delgado-Rodriguez M, Sillero-Arenas M, Martin-Moreno JM, Galvez-Vargas R. Oral contraceptives and cancer of the cervix uteri. A meta-analysis. Acta Obstet Gynecol Scand 1992;71:368-76.
129. Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370:1609-21.
130. Farr S, Folger SG, Paulen M, Tepper N, Whiteman M, Zapata L, Culwell K, Kapp N, Cansino C. U S. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization medical eligibility criteria for contraceptive use, 4th ed. MMWR Recomm Rep 59:1-86.
131. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003;89:493-8. (Pubitemid 36329240)
132. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642-5. (Pubitemid 27097428)
133. Oren E, Smith NL, Doggen CJ, Heckbert SR, Lemaitre RN. Body mass index and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2006;4:2273-5. (Pubitemid 44400310)
134. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-20.
135. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005;118:978-80. (Pubitemid 41297761)
136. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182-9. (Pubitemid 34522408)
137. Vaya A, Mira Y, Ferrando F, Contreras M, Estelles A, Espana F, et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002;118:255-9. (Pubitemid 34779546)
138. White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000;343:1758-64.
139. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004;91:683-9. (Pubitemid 38477447)
140. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
141. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000;5:265-74. (Pubitemid 32165465)
142. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139:289-96. (Pubitemid 47493087)
143. Blanco-Molina A, Trujillo-Santos J, Tirado R, Canas I, Riera A, Valdes M, et al. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost 2009;101:478-82.
144. Burkman RT, Fisher AC, Wan GJ, Barnowski CE, LaGuardia KD. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 2009;79:424-7.
145. Westhoff CL, Torgal AH, Mayeda ER, Stanczyk FZ, Lerner JP, Benn EK, Paik M. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol. 2010;116:275-83.
146. Culwell KR, Curtis KM, Del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol 2009;114:341-53.
147. World Health Organization. Selected practice recommendations for contraceptive use. 2nd ed. Geneva (Switzerland): World Health Organization; 2008.
148. Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol 2009;21:279-83.
149. Alonso A, Clark CJ. Oral contraceptives and the risk of multiple sclerosis: a review of the epidemiologic evidence. J Neurol Sci 2009;286:73-5.
150. Lange P, Parner J, Prescott E, Ulrik CS, Vestbo J. Exogenous female sex steroid hormones and risk of asthma and asthma-like symptoms: a cross sectional study of the general population. Thorax 2001;56:613-6. (Pubitemid 32706142)
151. Macsali F, Real FG, Omenaas ER, Bjorge L, Janson C, Franklin K, et al. Oral contraception, body mass index and asthma: a cross-sectional Nordic-Baltic population survey. J Allergy Clin Immunol 2009;123:391-7.
152. Sarfati J, de Vernejoul MC. Impact of combined and progestogen-only contraceptives on bone mineral density. Joint Bone Spine 2009; 76:134-8.
153. Lopez LM, Grimes DA, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev 2009:CD006033.
154. Institute of Medicine. New frontiers in contraceptive research: a blueprint for action. Washington (DC): National Academies Press; 2004.
155. Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 2009;94:1910-5.
156. Population Council. New and improved reproductive technologies. Population council: research that makes a difference. New York: Population Council, Center for Biomedical Research; 2010.
157. Mahabadi V, Amory JK, Swerdloff RS, Bremner WJ, Page ST, Sitruk-Ware R, et al. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab 2009;94:2313-20.
158. Ballagh SA, Brache V, Mauck C, Callahan MM, Cochon L, Wheeless A, et al. study of the functional performance, safety and acceptability of the BufferGel Duet. Contraception 2008;77:130-7.
159. Anderson DJ, Williams DL, Ballagh SA, Barnhart K, Creinin MD, Newman DR, et al. Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol 2009;61:121-9.
160. Schwartz JL, Ballagh SA, Creinin MD, Rountree RW, Kilbourne-Brook M, Mauck CK, et al. SILCS diaphragm: postcoital testing of a new single-size contraceptive device. Contraception 2008;78:237-44.
161. Ligt-Veneman NG, Tinga DJ, Kragt H, Brandsma G, van der Leij G. The efficacy of intratubal silicone in the Ovabloc hysteroscopic method of sterilization. Acta Obstet Gynecol Scand 1999;78:824-5. (Pubitemid 29486062)
162. Kerin JF, Carignan CS, Cher D. The safety and effectiveness of a new hysteroscopic method for permanent birth control: results of the first Essure pbc clinical study. Aust N Z J Obstet Gynaecol 2001;41:364-70. (Pubitemid 33100671)
163. Guha SK, Singh G, Ansari S, Kumar S, Srivastava A, Koul V, et al. Clinical trial of a vas deferens injectable contraceptive for the male. Contraception 1997;56:245-50. (Pubitemid 27516392)
164. Zaneveld LJD, De Castro MP, Faria G, et al. The soft hollow plug ("SHUG"): a potentially reversible vas deferens blocking device. In: Griffin PD, Rajalakshmi M, editors. Male contraception: present and future. New Delhi: New Age International; 1998.
165. Cui C, Stevens VC, Schwendeman SP. Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine. Vaccine 2007;25:500-9. (Pubitemid 44856092)
166. O'Rand MG, Widgren EE, Sivashanmugam P, Richardson RT, Hall SH, French FS, et al. Reversible immunocontraception in male monkeys immunized with eppin. Science 2004;306:1189-90. (Pubitemid 39488999)
167. Aitken RJ, Baker MA, Doncel GF, Matzuk MM, Mauck CK, Harper MJ. As the world grows: contraception in the 21st century. J Clin Invest 2008;118:1330-43.
168. van Mourik MS, Macklon NS, Heijnen CJ. Embryonic implantation: cytokines, adhesion molecules and immune cells in establishing an implantation environment. J Leukoc Biol 2009;85:4-19.